-β-D-glucuronopyranoside], GL) are the major bioactive components of Glycyrrhiza uralensis and possess multifarious notable biological activities. UDP-glycosyltransferase (UGT)-catalyzed glycosylation remarkably extends the structural and functional diversification of GA-glycoside derivatives. In this study, six glucosides (1-6) of GA and GL were synthesized using a Bacillus subtilis 168-originated flexible UDP-glycosyltransferase Bs-YjiC. Bs-YjiC could transfer a glucosyl moiety from UDP-glucose to the free C3 hydroxyl and/or C30 carboxyl groups of GA and GL and further elongate the C30 glucosyl chain via a β-1-2-glycosidic bond. Glycosylation significantly increased the water solubility of these novel glucosides by 4-90 folds. In vitro assays showed that GA monoglucosides (1 and 2) showed stronger antiproliferative activity against human liver cancer cells HepG2 and breast cancer cells MCF-7 than that of GL and GL glucosides. These findings provide significant insights into the important role of promiscuous UGTs for the enzymatic synthesis of novel bioactive GA derivatives.
Introduction
Triterpenoid saponins represent one of the largest groups of natural products with a structure consisting of a hydrophobic triterpene backbone and one or more sugar moieties attached to the hydroxyl and/or carboxyl groups through a β-glycosidic linkage [1, 2] . These molecules are widely distributed in higher plants and confer protective functions to the plants due to their anti-insect, antimicrobial, and anti-palatable activities [3] . Triterpenoid saponins are also the major bioactive compounds of many important traditional medicinal plants, including Glycyrrhiza uralensis, Panax ginseng, Saponaria vaccaria, Bupleurum falcatum, and Siraitia grosvenorii [4] [5] [6] [7] [8] . These natural products exhibit a wide range of notable biological actions, including anticancer, antifatigue, anti-inflammatory, antidiabetic, antiaging, antihypertensive, and immune-potentiating properties [9] .
Glycyrrhetinic acid (GA) and glycyrrhizin (GA-3-O-[β-D-glucuronopyranosyl-(1→2)-β-Dglucuronopyranoside], GL) are oleanane-type pentacyclic triterpenes. These compounds are the
Results and Discussion

Glycosylation of GA with Bs-YjiC
The recombinant Bs-YjiC was expressed in E. coli BL21 (DE3) and purified by one-step nickel affinity chromatography (Supplementary Information Figure S1 ). GA is the common aglycone of GL and the other triterpenoid saponins in G. uralensis [1] . Thus, Bs-YjiC was preliminarily used to catalyze the in vitro glycosylation of GA with UDPG as a sugar donor (Figure 1 ). Four new products (1-4) from the Bs-YjiC-catalyzed reactants were identified by HPLC, whereas no new products were detected in the control reactants catalyzed by crude extracts prepared from E. coli BL21 (DE3) expressing pET28a ( Figure 2A Figure 2B ). Microbial UGTs are generally flexible toward both the aglycones and sugar donors [27] . Thus, UDP-GlcNAc, UDP-Gal, and UDP-GlcA were also tested as possible sugar donors under identical conditions as those of GA and UDPG. Bs-YjiC was only able to catalyze UDP-Gal with low activity (approximately 9% relative activity against the reaction using UDPG as a sugar donor), whereas activity of Bs-YjiC toward UDP-GlcA and UDP-GlcNAc was not detected (Supplementary Information Figure S2 ). These results indicated that Bs-YjiC favorably used UDPG as a sugar donor and could distinguish the sugar moiety of UDP-sugars. To elucidate the regio-and stereospecificity of Bs-YjiC toward GA, products 1-4 were purified and their structures were confirmed by NMR analyse (Supplementary Information Figures S3-S22 ). For monoglucoside 1, the anomeric carbon signal C1′ (δC 95.6) shifted to higher field (~11.0 ppm) and the anomeric proton signal H1′ (δH 5.52) shifted to lower field (~1.2 ppm) than the corresponding signals in an alcoholic glycosidic bond, suggesting that the glucosyl moiety was esterified with the C30 carboxyl group of GA (Supplementary Information Table S1 ) [28] . Furthermore, the HMBC To elucidate the regio-and stereospecificity of Bs-YjiC toward GA, products 1-4 were purified and their structures were confirmed by NMR analyse (Supplementary Information Figures S3-S22 ). For monoglucoside 1, the anomeric carbon signal C1′ (δC 95.6) shifted to higher field (~11.0 ppm) and the anomeric proton signal H1′ (δH 5.52) shifted to lower field (~1.2 ppm) than the corresponding signals in an alcoholic glycosidic bond, suggesting that the glucosyl moiety was esterified with the C30 carboxyl group of GA (Supplementary Information Table S1 ) [28] . Furthermore, the HMBC To elucidate the regio-and stereospecificity of Bs-YjiC toward GA, products 1-4 were purified and their structures were confirmed by NMR analyse (Supplementary Information Figures S3-S22 ). For monoglucoside 1, the anomeric carbon signal C1 (δ C 95.6) shifted to higher field (~11.0 ppm) and the anomeric proton signal H1 (δ H 5.52) shifted to lower field (~1.2 ppm) than the corresponding signals in an alcoholic glycosidic bond, suggesting that the glucosyl moiety was esterified with the C30 carboxyl group of GA (Supplementary Information Table S1 ) [28] . Furthermore, the HMBC correlations of the anomeric proton signal H1 (δ H 5.52, d, J = 8.20 Hz) with C30 (δ C 176.7) of GA backbone reconfirmed that product 1 was GA-30-O-β-D-glucopyranoside. For monoglucoside 2, a notable downfield 13 C-shift (~11.2 ppm, "glycosylation shift") at C3 (δ C 90.4) indicated that a glucosyl moiety was attached to the C3 hydroxyl group of GA (Supplementary Information Table S2 ) [29] . The HMBC correlations between the anomeric proton signal H1 (δ H 4.32, d, J = 7.80 Hz) with C3 (δ C 90.4) suggested that product 2 was GA-3-O-β-D-glucopyranoside. Diglucoside 3 exhibited spectroscopic data similar to those of products 1 and 2 (Supplementary Information Table S3 ). The observation of significant downfield shift of C3 (~11.1 ppm) of GA backbone and upfield shift of the anomeric carbon signal C1 (~11.0 ppm) suggested that a glucosyl moiety was attached to the C3 hydroxyl and C30 carboxyl groups of GA, respectively. The HMBC correlations of the anomeric proton signal H1 (δ 
The coupling constants of the anomeric protons (J = 7.80-8.20 Hz) of products 1-4 indicated that all the glucosyl moieties adopted the β-configuration, which was consistent with the inverting mechanism of UGTs [30] . All the four glucosides (1-4) of GA were unnatural products, and products 3 and 4 were synthesized in this study for the first time. Thus, Bs-YjiC from B. subtilis 168 was the first reported UGT that could transfer a glucosyl moiety from UDPG to the free C3 hydroxyl and/or C30 carboxyl groups of GA and further elongate the C30 glucosyl chain via a β-1-2-glycosidic bond. Glycosylation is the prominent biological mechanism for structural and functional diversity of triterpene saponins [2] . Thus, unnatural products 1-4 synthesized in this study should also possess biological and pharmacological activities that are the same as those as other natural GA glycosides that are usually decorated with glucuronyl, xylosyl, or rhamnosyl moieties.
Glycosylation of GL with Bs-YjiC
GL is the most representative glycoside of GA (Figure 1 ), which contains a free C30 carboxyl group and two glucuronyl moieties attached to the C3 hydroxyl via a β-1-2-glycosidic bond [31] . Therefore, a reaction by incubation of GL with UDPG was further performed under conditions identical to those of GA. Two new products (5 and 6) from the Bs-YjiC-catalyzed reaction mixtures were identified by HPLC ( Figure 3A Table S6 ). In the COSY spectra, signals at δC 94.0 and δC 79.2 were assigned to the C1‴ and C2‴ of the 30-O-inner glucosyl moiety. The observation of significant upfield shift of C1‴ (~12.6 ppm, "glycosylation shift") was consistent with the formation of ester-linked glycosidic bond between the 30-O-inner glucosyl moiety and C30 carboxyl group of GA backbone. By comparison of the 1 H NMR and 13 C NMR spectra of products 5 and 6, significant glycosylation shifts were also observed for C1‴ (−1.5 ppm), C2‴ (+5. Table S6 ). In the COSY spectra, signals at δ C 94.0 and δ C 79.2 were assigned to the C1 and C2 of the 30-O-inner glucosyl moiety. The observation of significant upfield shift of C1 (~12.6 ppm, "glycosylation shift") was consistent with the formation of ester-linked glycosidic bond between the 30-O-inner glucosyl moiety and C30 carboxyl group of GA backbone. By comparison of the 1 H NMR and 13 C NMR spectra of products 5 and 6, significant glycosylation shifts were also observed for C1 (−1.5 ppm), C2 (+5. 
Kinetic Parameters of Bs-YjiC toward GA and GL
To evaluate the affinity and catalytic efficiency of Bs-YjiC, the kinetic parameters of Bs-YjiC toward GA and GL were determined by nonlinear-regression analysis (Supplementary Information Figure  S33 ). The Michaelis constant (K m ) value of Bs-YjiC toward GA (245.00 µM) was about 5-fold higher than that of Bs-YjiC toward GL (58.73 µM) ( Table 1 ), indicating that the affinity of Bs-YjiC against GL was much higher than that of Bs-YjiC against GA. However, the turn over number (k cat ) of Bs-YjiC against GA (3.36 s −1 ) was approximately 11-fold higher than that of GL (0.31 s −1 ). Consequently, the catalytic efficiency (k cat /K m ) of Bs-YjiC against GA (1.37 × 10 4 s −1 M −1 ) was about 2-fold higher than that of Bs-YjiC against GL (0.53 × 10 4 s −1 M −1 ). Compared with the kinetic parameters of B. vulgaris UGT73C11 and G. uralensis UGT73F17 [20, 22] , the catalytic efficiencies of Bs-YjiC against GA and GL were considerably high, indicating that Bs-YjiC was an effective biocatalyst for glycosylation of GA and GL. Currently, all the key genes involved in the biosynthetic pathway of GA have been cloned and functionally characterized [33, 34] . An engineered yeast cell factory that can produce substantial amounts of GA has recently been constructed by introducing the whole biosynthetic pathway of GA into S. cerevisiae [8] . Thus, it will be of particular interest to introduce Bs-YjiC or an engineered Bs-YjiC into the GA-producing chassis cell factory to synthesize these unnatural GA glucosides or a specific GA glucoside via protein engineering, synthetic biology, and metabolic engineering. 
Solubility of the Glycosylated Products
The poor solubility of natural products resulted in a short retention time as well as a low absorption in the intestine [35, 36] . Glycosylation can be used to enhance the solubility of hydrophobic natural products and thus to improve their bioavailabilities and pharmacodynamics [37] . Therefore, the effect of Bs-YjiC-catalyzed glycosylation on water solubility of GA and GL glucosides was evaluated ( Table 2 ). As could be expected, the attachment of glucosyl moieties to GA and GL significantly increased their water solubility. The solubility of GA was limited to 29 µM, whereas the corresponding glucosides could be dissolved to 58 µM (product 1), 242 µM (product 2), 2022 µM (product 3), and 98326 µM (product 4), respectively. Notably, products 1 and 2 were structural isomers; however, product 2 exhibited 4 times more soluble than that of product 1. These results were in agreement with previous studies that glycosylation position influenced solubility [38, 39] . Compared with the water solubility of GL (1526 µM), the water solubility of product 5 (136,698 µM) was significantly increased by 90 times after the C30 carboxyl of GL was decorated with only one glucosyl moiety. ND ND ND represented that water solubility was not determined because we could not prepare enough product 6.
In Vitro Cytotoxicity of the Glycosylated Products
Sugar moieties appended to natural products not only enhance their solubility but also influence their pharmacological efficacies and/or molecular mechanisms of action [40] . GL as the most representative glycosylated product of GA has been clinically used as a hepatoprotective medicine for the treatment of chronic hepatitis, liver cirrhosis and hepatic carcinoma [12] . Thus, the bioactivity of all the novel GA and GL glucosides against human liver cancer cells HepG2 and breast cancer cells MCF-7 was evaluated and compared with that of GL (Table 3) . Monoglucosides 1 and 2 and GL showed remarkable inhibitory effects on HepG2, with IC 50 values ranged from 7.2 to 37.3 µM. Similarly, monoglucosides 1 and 2 and GL can also inhibit the proliferation of MCF-7 with IC 50 values of 7.7, 13.0, and 113.7 µM, respectively. However, products 3-6 were inactive toward both HepG2 and MCF-7 (cut-off 200 µM). In addition, both monoglucosides 1 and 2 exhibited stronger cytotoxicity against HepG2 and MCF-7 than those of GL. The present study was identical to the previous findings on GA-3-O-β-D-glucuronide (a hydrolyzed derivative of GL), which showed stronger inhibitory activity against diverse human cancer cells than that of GL [41, 42] . Notably, products 1 and 2 were isomers of GA; however, product 1 exhibited stronger activity against HepG2 (~3.5 folds) and MCF-7 (~1.7 folds) than those of product 2, indicating that the binding position of the glucosyl moiety significantly influenced the cytotoxic activities of GA glucosides. 
Materials and Methods
Chemicals and Reagents
GA and GL were purchased from Chengdu Biopurify Phytochemicals Co., Ltd. (Chengdu, China). UDPG, UDP-N-acetylglucosamine (UDP-GlcNAc), UDP-galactose (UDP-Gal), and UDP-glucuronic acid (UDP-GlcA) were obtained from Sigma-Aldrich (St. Louis, USA). Human liver cancer cells HepG2 and breast cancer cells MCF-7 preserved in our lab were grown in Dulbecco's modified Eagle's medium (GIBCO, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum, 100 µg mL −1 streptomycin, and 100 units mL −1 penicillin [24] .
In Vitro Enzymatic Glycosylation
Expression of Bs-YjiC (GenBank accession no. NP_389104) was performed as reported previously [24] . Recombinant Escherichia coli BL21 (DE3) cells harboring plasmid pET28a-Bs-YjiC were inoculated into Luria-Bertani medium supplemented with 50 mg L −1 kanamycin and cultured at 37 • C and 200 rpm until the OD 600 reached approximately 0.8. The N-terminal His 6 -tagged Bs-YjiC was induced with 0.2 mM isopropyl-β-D-thiogalactopyranoside at 16 • C and 200 rpm for 16-18 h. The recombinant cells were harvested by centrifugation at 5500 rpm for 10 min at 4 • C and resuspended in binding buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 25 mM imidazole). After disrupted with a French press, the cell lysates were centrifuged at 15,000 rpm for 60 min at 4 • C. Then, the supernatant containing N-terminal His 6 -tagged Bs-YjiC was purified by Ni-NTA agarose affinity column connected to an AKTA Purifier system (GE Healthcare, Chicago, IL, USA).
The glycosylation reaction was performed in 300 µL reaction buffer (50 mM Tris-HCl, pH 8.0) containing 1 mM GA or GL, 5 mM diverse UDP-sugars (UDPG, UDP-GlcA, UDP-Gal, or UDP-GlcNAc), 10 mM MgCl 2 , and 10 µg purified Bs-YjiC. After incubation at 40 • C for 0.5 h, the reactions were quenched by adding equal volume of methanol and then analyzed by high-performance liquid chromatography (HPLC) or HPLC coupled with quantitative time of flight-high-resolution electrospray ionization-mass spectrometry (HPLC-ESI-MS) as reported previously [29] .
Kinetic Parameters of Bs-YjiC
Kinetic studies (300 µL) of Bs-YjiC toward GA and GL were conducted with purified Bs-YjiC (1 µg for GA and 2 µg for GL), 10% DMSO (v/v), 50 mM Tris-HCl (pH 8.0), 10 mM MgCl 2 , 10 mM UDPG, and varying concentrations of GA (75-800 µM) or GL (12.5-300 µM). The reactions were incubated at 40 • C for 20 min and terminated by adding equal volume of methanol.
Structural Analysis of GA and GL Glucosides
Scale-up preparation (500 mL) of products 1-6 was described above. The glycosylated products were purified by preparative HPLC system coupled with a preparative reverse-phase C18 column (21.2 × 250 mm, 5 µm particle, Welch, Shanghai, China). The preparative column was eluted with distilled water (solvent A) and methanol (solvent B) by using a gradient program of 40-100% B in 0-60 min. The purified fractions containing target GA or GL glucosides were pooled and concentrated by using the rotary evaporator and vacuum freeze drier. The dried powders were dissolved in methanol-d 4 . NMR experiments were performed on a Bruker DMX600 NMR spectrometer (Bruker, Bremen, Germany).
Water Solubility Tests
Water solubility of GA, GL, and the respective glucosides was determined as previously described [42] . Excess amounts of the respective glycosylated products, GA, or GL were added in distilled water. The suspensions were extensively mixed by vortexed for 2 h, equilibrated overnight at 25 • C, and centrifuged at 14,000 rpm for 10 min at room temperature. The supernatants were diluted with appropriate volumes of methanol and tested with HPLC method described above.
In Vitro Cytotoxic Assays
In vitro cytotoxic activities of GA and GL glucosides against human liver cancer cells HepG2 and breast cancer cells MCF-7 were evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as reported in our previous study [43] . GL as the most representative glycosylated product of GA and a first-line anticancer drug for the treatment of hepatic carcinoma was used as a positive control.
Conclusions
In summary, Bs-YjiC from B. subtilis 168 was the first reported UGT that can glycosylate the C3 hydroxyl and/or C30 carboxyl of GA and GL and elongate the C30 glucosyl chain via a β-1-2-glycosidic bond. GA-30-O-β-D-glucopyranoside (1) and GA-3-O-β-D-glucopyranoside (2) displayed stronger cytotoxic activity against cancer cell lines than that of GL. In vivo anticancer activity of monoglucosides 1 and 2 should be studied further. Table S1 . 1 H-and 13 C-NMR spectral data for product 1 (Methanol-d 4 , 600 MHz). Table S2 . 1 H-and 13 C-NMR spectral data for product 2 (Methanol-d 4 , 600 MHz). Table S3 . 1 H-and 13 C-NMR spectral data for product 3 (Methanol-d 4 , 600 MHz). Table S4 . 1 H-and 13 C-NMR spectral data for product 4 (Methanol-d 4 , 600 MHz). Table S5 . 1 H-and 13 C-NMR spectral data for product 5 (Methanol-d 4 , 600 MHz). Table S6 . 1 H-and 13 C-NMR spectral data for product 6 (Methanol-d 4 , 600 MHz). Figure S1 . SDS-PAGE analysis of purified Bs-YjiC. Figure S2 . Assessment of sugar donors of Bs-YjiC using GA as the aglycon. Figure S3 . 1 H NMR spectrum of product 1 (Methanol-d 4 ) . Figure S4 . 13 C NMR spectrum of product 1 (Methanol-d 4 ) . Figure S5 . HMBC spectrum of product 1 (Methanol-d 4 ) . Figure S6 . HSQC spectrum of product 1 (Methanol-d 4 ) . Figure S7 . COSY NMR spectrum of product 1 (Methanol-d 4 ). Figure S8 . 1 H NMR spectrum of product 2 (Methanol-d 4 ) . Figure S9 . 13 C NMR spectrum of product 2 (Methanol-d 4 ) . Figure S10 . HMBC spectrum of product 2 (Methanol-d 4 ) . Figure  S11 . HSQC NMR spectrum of product 2 (Methanol-d 4 ) . Figure S12 . COSY spectrum of product 2 (Methanol-d 4 ). Figure S13 . 1 H NMR spectrum of product 3 (Methanol-d 4 ) . Figure S14 . 13 C NMR spectrum of product 3 (Methanol-d 4 ) . Figure S15 . HMBC spectrum of product 3 (Methanol-d 4 ) . Figure S16 . HSQC spectrum of product 3 (Methanol-d 4 ) . Figure S17 . COSY spectrum of product 3 (Methanol-d 4 ). Figure S18 . 1 H NMR spectrum of product 4 (Methanol-d 4 ) . Figure S19 . 13 C NMR spectrum of product 4 (Methanol-d 4 ) . Figure S20 . HMBC spectrum of product 4 (Methanol-d 4 ) . Figure S21 . HSQC spectrum of product 4 (Methanol-d 4 ) . Figure S22 . COSY spectrum of product 4 (Methanol-d 4 ). Figure S23 . 1 H NMR spectrum of product 5 (Methanol-d 4 ) . Figure S24 . 13 C NMR spectrum of product 5 (Methanol-d 4 ) . Figure S25 . HMBC spectrum of product 5 (Methanol-d 4 ) . Figure S26 . HSQC spectrum of product 5 (Methanol-d 4 ) . Figure S27 . COSY spectrum of product 5 (Methanol-d 4 ) . Figure S28 . 1 H NMR spectrum of product 6 (Methanol-d 4 ) . Figure S29 . 13 C NMR spectrum of product 6 (Methanol-d 4 ) . Figure  S30 . HMBC spectrum of product 6 (Methanol-d 4 ) . Figure S31 . HSQC NMR spectrum of product 6 (Methanol-d 4 ) . Figure S32 . COSY spectrum of product 6 (Methanol-d 4 ) . 
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